{"id":"cannabis-oil","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Dry mouth"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Impaired cognition"},{"rate":null,"effect":"Anxiety or paranoia (THC-dominant formulations)"}]},"_chembl":{"chemblId":"CHEMBL2107910","moleculeType":"Unknown"},"_dailymed":{"setId":"7f960d4c-ad09-4dc8-b272-66e4df26ace8","title":"NYX PROFESSIONAL MAKEUP BARE WITH ME DAILY MOISTURIZING PRIMER WITH CANNABIS SATIVA SEED OIL SPF 30 (AVOBENZONE, HOMOSALATE, OCTISALATE AND OCTOCRYLENE) CREAM [L'OREAL USA PRODUCTS INC]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The active cannabinoids in cannabis oil bind to CB1 receptors in the brain and nervous system and CB2 receptors in immune cells and peripheral tissues. This activation modulates neurotransmitter release, reduces inflammatory cytokine production, and alters pain signal processing. The specific therapeutic effects depend on the THC:CBD ratio and the condition being treated.","oneSentence":"Cannabis oil contains cannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems to modulate pain, inflammation, and other physiological processes.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:04:47.756Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic pain"},{"name":"Chemotherapy-induced nausea and vomiting"},{"name":"Multiple sclerosis-related spasticity"},{"name":"Epilepsy (particularly in pediatric populations)"}]},"trialDetails":[{"nctId":"NCT07459920","phase":"PHASE2","title":"Cannabis extrAct in Oncology Patients for the Treatment of TUmor Related Symptom Burden","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2026-04-01","conditions":"Advanced Malignant Solid Tumor","enrollment":156},{"nctId":"NCT05261321","phase":"PHASE1","title":"Cannabis and Polysubstance Use: Response Inhibition and Stress Exposure","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of British Columbia","startDate":"2022-10-15","conditions":"Healthy","enrollment":20},{"nctId":"NCT05066308","phase":"PHASE2","title":"Cannabidiol for Reduction of Brain Neuroinflammation","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2022-01-04","conditions":"Back Pain, Depressive Symptoms","enrollment":80},{"nctId":"NCT07362407","phase":"","title":"Analysis of the Therapeutic and Clinical Profile of Cannabinoid Treatments: A Real-World Study","status":"NOT_YET_RECRUITING","sponsor":"Santa Catarina Federal University","startDate":"2026-02","conditions":"Chronic Pain, Depression Disorders, Anxiety Disorders","enrollment":384},{"nctId":"NCT05041647","phase":"PHASE2","title":"Cannabinoids as a Treatment for Insomnia in Major Depression","status":"COMPLETED","sponsor":"St. Joseph's Healthcare Hamilton","startDate":"2023-08-28","conditions":"Insomnia, Depressive Disorder, Major, Sleep Disorder","enrollment":14},{"nctId":"NCT06261489","phase":"PHASE2","title":"Cannabis (THC vs. CBD) in Multiple Sclerosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Calgary","startDate":"2025-12-05","conditions":"Multiple Sclerosis","enrollment":30},{"nctId":"NCT05615389","phase":"PHASE1, PHASE2","title":"Pilot Study of MC in Paediatric Palliative Care","status":"RECRUITING","sponsor":"Murdoch Childrens Research Institute","startDate":"2024-02-19","conditions":"Palliative Care","enrollment":10},{"nctId":"NCT05299944","phase":"PHASE2","title":"Reducing Pain and Opioid Use With CBD","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2022-03-08","conditions":"Opioid Use Disorder","enrollment":126},{"nctId":"NCT07257939","phase":"PHASE3","title":"NTI164 in Autism Spectrum Disorder","status":"NOT_YET_RECRUITING","sponsor":"Fenix Innovation Group","startDate":"2026-07-01","conditions":"Autism, Autism Spectrum Disorder, Autism Disorder","enrollment":98},{"nctId":"NCT07199218","phase":"PHASE2","title":"Placebo-Controlled Study of Terpenes-Enriched Cannabis Oil T1/C28 for Children With Autism","status":"RECRUITING","sponsor":"Bazelet Nehushtan LtD.","startDate":"2025-10-05","conditions":"Autism, Autism Spectrum Disorder","enrollment":78},{"nctId":"NCT04816994","phase":"PHASE3","title":"Effect of Cannabis Extract on Acute Radicular Pain and on Analgesic Requirement","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2018-01-07","conditions":"Acute Radicular Back Pain, Cannabis","enrollment":200},{"nctId":"NCT07194018","phase":"","title":"Use of Cannabis Oil in Fibromyalgia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Azienda Ospedaliera SS. Antonio e Biagio e Cesare Arrigo di Alessandria","startDate":"2024-10-19","conditions":"Fibromyalgia, Pain Management, Cannabis","enrollment":65},{"nctId":"NCT03948074","phase":"PHASE2","title":"Cannabis For Cancer-Related Symptoms","status":"COMPLETED","sponsor":"Pippa Hawley","startDate":"2021-02-01","conditions":"Pain, Nausea, Anxiety","enrollment":91},{"nctId":"NCT06863740","phase":"NA","title":"Using Cannabis to Treat Restless Legs Syndrome","status":"RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2025-07-25","conditions":"Restless Leg Syndrome (RLS)","enrollment":30},{"nctId":"NCT06475001","phase":"PHASE2","title":"Dose-Response Characterization of VER-01 in the Treatment of Patients With Chronic Non-specific Low Back Pain","status":"COMPLETED","sponsor":"Vertanical GmbH","startDate":"2024-06-28","conditions":"Chronic Non-specific Low Back Pain","enrollment":652},{"nctId":"NCT04659278","phase":"NA","title":"Endourage Complete Spectrum Oral Mucosal Drops (OMD) in Adults Desiring a Reduction in Ethanol Use","status":"WITHDRAWN","sponsor":"Endourage, LLC","startDate":"2025-09","conditions":"Alcohol Drinking, Alcohol Use, Unspecified, Alcohol Abstinence","enrollment":""},{"nctId":"NCT05324982","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of CHI-914 in Healthy Participants","status":"RECRUITING","sponsor":"Johns Hopkins University","startDate":"2022-08-09","conditions":"Behavioral Pharmacology of Cannabis","enrollment":30},{"nctId":"NCT07023744","phase":"PHASE2","title":"CANnabinoids for Drug Resistant Epilepsy (DRE) in Adults and Children","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","startDate":"2025-10-01","conditions":"Drug Resistant Epilepsy","enrollment":90},{"nctId":"NCT05337033","phase":"PHASE2","title":"Cannabis for Chronic Headaches in Adolescents: the CAN-CHA Trial","status":"RECRUITING","sponsor":"University of Manitoba","startDate":"2024-10-11","conditions":"Chronic Migraine","enrollment":20},{"nctId":"NCT05754840","phase":"PHASE1, PHASE2","title":"CANnabinoids in Pediatric ONCology","status":"NOT_YET_RECRUITING","sponsor":"University of Manitoba","startDate":"2025-06","conditions":"Childhood Cancer, Cancer","enrollment":60},{"nctId":"NCT06946940","phase":"PHASE2","title":"Biosignature of the Response to Treatment With Cannabis Oil in Individuals With Fibromyalgia","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2024-05-30","conditions":"Fibromyalgia","enrollment":150},{"nctId":"NCT06115603","phase":"PHASE2","title":"The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder","status":"RECRUITING","sponsor":"University of Arkansas, Fayetteville","startDate":"2024-12-14","conditions":"Attention-Deficit/Hyperactivity Disorder","enrollment":76},{"nctId":"NCT06807762","phase":"PHASE1","title":"Safety and Pharmacokinetics of Extrato de Cannabis Sativa GreenCare","status":"RECRUITING","sponsor":"GreenCare Pharma","startDate":"2025-03-18","conditions":"Healthy","enrollment":72},{"nctId":"NCT03825965","phase":"PHASE3","title":"Cannabinoids vs. Placebo on Persistent Post-surgical Pain Following TKA: A Pilot RCT","status":"COMPLETED","sponsor":"McMaster University","startDate":"2023-05-03","conditions":"Knee Osteoarthritis","enrollment":39},{"nctId":"NCT03984565","phase":"PHASE2","title":"PAIN: a Project Assessing the Impact of a Novel Cannabinoid Product","status":"RECRUITING","sponsor":"Staci Gruber, Ph.D.","startDate":"2024-06-27","conditions":"Chronic Pain","enrollment":25},{"nctId":"NCT05743985","phase":"NA","title":"Efficacy and Safety of Hemp-derived, Full Spectrum Cannabigerol (CBG) in Adults","status":"COMPLETED","sponsor":"Formula30A LLC","startDate":"2022-08-01","conditions":"Health, Subjective, Inflammatory Response, Adverse Effect","enrollment":69},{"nctId":"NCT05416697","phase":"PHASE3","title":"Effectiveness of Cannabinoids on Appetite in Scleroderma","status":"COMPLETED","sponsor":"Khon Kaen University","startDate":"2022-11-09","conditions":"Systemic Sclerosis, Malnutrition, Loss of Appetite","enrollment":30},{"nctId":"NCT05985850","phase":"PHASE2","title":"Evaluating Tetrahydrocannabinol as an Adjunct to Opioid Agonist Therapy","status":"RECRUITING","sponsor":"BC Centre on Substance Use","startDate":"2024-05-23","conditions":"Opioid Use Disorder, Methadone, Cannabis","enrollment":24},{"nctId":"NCT06435299","phase":"PHASE3","title":"Efficacy and Tolerance of Cannabidiol in Patients with Severe Pruritus: a Multicenter, Double-blind, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Brest","startDate":"2025-05-01","conditions":"Pruritus","enrollment":218},{"nctId":"NCT06379971","phase":"PHASE1","title":"Maternal Choline Supplementation and Cannabis Use During Pregnancy: Impact on Early Brain Development","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-11-25","conditions":"Child Development, Cannabis Use","enrollment":140},{"nctId":"NCT05432206","phase":"PHASE2, PHASE3","title":"MEDical CANnabis for Improving Symptoms During Severe DEMentia Disorders in Long-term Care Facility in Geneva","status":"COMPLETED","sponsor":"Fondation pour l'accueil et l'hébérement des personnes âgées","startDate":"2023-09-29","conditions":"Dementia with Behavioral Disturbance","enrollment":27},{"nctId":"NCT05092191","phase":"PHASE2","title":"Cannabis as a Complementary Treatment in Multiple Sclerosis","status":"RECRUITING","sponsor":"Centre hospitalier de l'Université de Montréal (CHUM)","startDate":"2022-11-10","conditions":"Multiple Sclerosis","enrollment":250},{"nctId":"NCT04984278","phase":"PHASE3","title":"Evaluation of the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2021-08-16","conditions":"Spasticity With Multiple Sclerosis","enrollment":56},{"nctId":"NCT06629389","phase":"PHASE2","title":"Clinical Trial with Cannabidiol (Kanbis®) for Parkinson Disease Symptoms","status":"RECRUITING","sponsor":"Laboratorio Elea Phoenix S.A.","startDate":"2024-11-28","conditions":"Parkinson Disease","enrollment":88},{"nctId":"NCT03337503","phase":"PHASE2","title":"Safety and Efficacy of Medical Cannabis Oil in the Treatment of Patients with Chronic Pain","status":"TERMINATED","sponsor":"Santé Cannabis","startDate":"2018-01-29","conditions":"Chronic Pain","enrollment":161},{"nctId":"NCT05184478","phase":"PHASE1, PHASE2","title":"Is Medicinal Cannabis an Effective Treatment for Tourette Syndrome in Adolescents? a Pilot Study","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-05-16","conditions":"Tourette Syndrome in Adolescence","enrollment":10},{"nctId":"NCT05873933","phase":"NA","title":"An Investigation of a Multi-Function Skincare Product to Improve Aging, Eczema, and Acne Outcomes","status":"WITHDRAWN","sponsor":"Hemptress","startDate":"2024-07-01","conditions":"Acne, Eczema, Skin Aging","enrollment":""},{"nctId":"NCT04873453","phase":"PHASE2","title":"CBD for the Treatment of Alcohol Use Disorder","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2021-08-30","conditions":"Alcohol Use Disorder","enrollment":45},{"nctId":"NCT05822362","phase":"PHASE2","title":"CBD for Individuals at Risk for Alzheimer's Disease","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-01-19","conditions":"Mild Cognitive Impairment","enrollment":236},{"nctId":"NCT05613608","phase":"PHASE2, PHASE3","title":"Alcohol Use Disorder and Cannabidiol","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2023-04-30","conditions":"Alcohol Use Disorder","enrollment":180},{"nctId":"NCT06542445","phase":"PHASE2","title":"The Safety and Efficacy of Terpene-enriched Cannabidiol (CBD) Oil in ADHD","status":"RECRUITING","sponsor":"Bazelet Nehushtan LtD.","startDate":"2024-08-22","conditions":"Attention Deficit Hyperactivity Disorder (ADHD)","enrollment":120},{"nctId":"NCT05212493","phase":"PHASE3","title":"The Effects of Medical Cannabis in Children With Autistic Spectrum Disorder","status":"COMPLETED","sponsor":"Assaf-Harofeh Medical Center","startDate":"2019-11-14","conditions":"Autism Spectrum Disorder","enrollment":128},{"nctId":"NCT05322941","phase":"PHASE2","title":"Effect of AEF0117 on Treatment-seeking Patients With Cannabis Use Disorder (CUD)","status":"COMPLETED","sponsor":"Aelis Farma","startDate":"2022-05-06","conditions":"Marijuana Abuse","enrollment":333},{"nctId":"NCT06526208","phase":"PHASE2","title":"Investigating a Marijuana-based Compound as a Treatment for Anxiety in Autistic Adults","status":"NOT_YET_RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2024-10-01","conditions":"Autism Spectrum Disorder, Anxiety","enrollment":108},{"nctId":"NCT06518434","phase":"PHASE2","title":"A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients","status":"RECRUITING","sponsor":"University Medical Center Groningen","startDate":"2021-04-15","conditions":"Hepatocellular Carcinoma, Cannabis","enrollment":20},{"nctId":"NCT06217146","phase":"NA","title":"A Medical Cannabis Oil for Treatment of Agitation and Disruptive Behaviors in Subjects With Dementia.","status":"TERMINATED","sponsor":"M. H MediCane Ltd.","startDate":"2022-10-12","conditions":"Agitation,Psychomotor, Disruptive Behavior, Dementia","enrollment":24},{"nctId":"NCT04406948","phase":"PHASE2","title":"Study of Safety and Efficacy of MGCND00EP1 as an Add on Treatment in Children and Adolescents With Resistant Epilepsies","status":"WITHDRAWN","sponsor":"MGC Pharmaceuticals d.o.o","startDate":"2024-05-30","conditions":"Resistant Epilepsy, Drug, Adolescent Epilepsy, Children Epilepsy","enrollment":""},{"nctId":"NCT04634136","phase":"NA","title":"Full-spectrum Medical Cannabis for Treatment of Spasticity in Patients With Severe Forms of Cerebral Palsy","status":"COMPLETED","sponsor":"University Medical Centre Ljubljana","startDate":"2020-10-15","conditions":"Children, Adult, Spastic Cerebral Palsy, Quality of Life","enrollment":55},{"nctId":"NCT04203498","phase":"PHASE3","title":"Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis","status":"TERMINATED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-10-01","conditions":"Multiple Sclerosis (MS)","enrollment":139},{"nctId":"NCT02283281","phase":"PHASE2, PHASE3","title":"Anesthetic Premedication With a Cannabis Extract (Cannapremed)","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2015-05","conditions":"Pain, Postoperative, Postoperative Nausea and Vomiting, Anxiety","enrollment":200},{"nctId":"NCT05344170","phase":"PHASE1, PHASE2","title":"Cannabinol Use in Patients With Insomnia Disorder","status":"COMPLETED","sponsor":"Woolcock Institute of Medical Research","startDate":"2022-08-24","conditions":"Insomnia Disorder","enrollment":20},{"nctId":"NCT06213064","phase":"","title":"A Direct-to-Consumer Study Investigating the Effect of Specific Cannabinoid Products on Motivation, Energy Level, Focus, and Appetite in Healthy Adults","status":"UNKNOWN","sponsor":"Phylos Bioscience, Inc.","startDate":"2023-08-14","conditions":"Motivation","enrollment":58},{"nctId":"NCT06159387","phase":"PHASE4","title":"Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts","status":"UNKNOWN","sponsor":"University of Sao Paulo General Hospital","startDate":"2023-10-23","conditions":"Cocaine Dependence","enrollment":60},{"nctId":"NCT04603781","phase":"PHASE2, PHASE3","title":"CBD Oil for Reducing Emotional Impact of COVID-19","status":"SUSPENDED","sponsor":"University of Texas at Austin","startDate":"2020-12-04","conditions":"Anxiety Depression, Alcohol Abuse, Substance Abuse","enrollment":200},{"nctId":"NCT04657666","phase":"PHASE3","title":"Trial to Evaluate the Effect of Nabiximols Oromucosal Spray on Clinical Measures of Spasticity in Participants With Multiple Sclerosis","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2020-12-21","conditions":"Spasticity in Participants With Multiple Sclerosis","enrollment":68},{"nctId":"NCT03972124","phase":"PHASE2","title":"Cannabis for the Prophylactic Treatment of Migraine","status":"NOT_YET_RECRUITING","sponsor":"University of Calgary","startDate":"2024-06","conditions":"Chronic Migraine","enrollment":120},{"nctId":"NCT00681538","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2008-01","conditions":"Spasticity, Multiple Sclerosis","enrollment":572},{"nctId":"NCT01606137","phase":"PHASE3","title":"A Study of the Long-term Safety of Sativex Use","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2002-02","conditions":"Multiple Sclerosis, Spasticity, Pain","enrollment":507},{"nctId":"NCT00702468","phase":"PHASE3","title":"Evaluate the Maintenance of Effect After Long-term Treatment With Sativex® in Subjects With Symptoms of Spasticity Due to Multiple Sclerosis","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2007-11","conditions":"Spasticity, Multiple Sclerosis","enrollment":36},{"nctId":"NCT00711646","phase":"PHASE3","title":"A Study of Sativex® for Relief of Spasticity in Subjects With Multiple Sclerosis.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2002-06","conditions":"Spasticity, Multiple Sclerosis","enrollment":189},{"nctId":"NCT00710554","phase":"PHASE3","title":"A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2005-08","conditions":"Pain, Peripheral Neuropathy","enrollment":246},{"nctId":"NCT00710424","phase":"PHASE3","title":"A Study of Sativex® for Pain Relief Due to Diabetic Neuropathy","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2005-07","conditions":"Pain, Diabetic Neuropathy","enrollment":297},{"nctId":"NCT00713817","phase":"PHASE3","title":"A Study to Determine the Maintenance of Effect After Long-term Treatment of Sativex® in Subjects With Neuropathic Pain","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2007-03","conditions":"Pain, Peripheral Neuropathy","enrollment":19},{"nctId":"NCT01599234","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Sativex in Relieving Symptoms of Spasticity Due to Multiple Sclerosis","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2005-03","conditions":"Multiple Sclerosis","enrollment":337},{"nctId":"NCT00713323","phase":"PHASE3","title":"A Study to Compare the Safety and Tolerability of Sativex® in Patients With Neuropathic Pain.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2005-10","conditions":"Pain, Peripheral Neuropathy","enrollment":380},{"nctId":"NCT03024827","phase":"PHASE1","title":"Cannabidiol in Children With Refractory Epileptic Encephalopathy","status":"UNKNOWN","sponsor":"University of Saskatchewan","startDate":"2017-04-26","conditions":"Epileptic Encephalopathy","enrollment":20},{"nctId":"NCT05219370","phase":"PHASE2","title":"Treatment With Cannabis Oil Containing CBD, THC, CBDV or CBG vs. Placebo of Persons With ADHD","status":"TERMINATED","sponsor":"Brlev Agricultural Crops Ltd","startDate":"2022-07-31","conditions":"ADHD, Hyperactivity, Attention Deficit","enrollment":8},{"nctId":"NCT01361607","phase":"PHASE3","title":"Sativex® for Relieving Persistent Pain in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-05-27","conditions":"Pain, Advanced Cancer","enrollment":399},{"nctId":"NCT01337089","phase":"PHASE3","title":"Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-01-19","conditions":"Pain, Advanced Cancer","enrollment":660},{"nctId":"NCT01424566","phase":"PHASE3","title":"A Two-Part Study of Sativex® Oromucosal Spray for Relieving Uncontrolled Persistent Pain in Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2012-06-29","conditions":"Pain, Advanced Cancer","enrollment":406},{"nctId":"NCT00711880","phase":"PHASE3","title":"A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2002-05","conditions":"Pain, Peripheral Neuropathy","enrollment":125},{"nctId":"NCT03690791","phase":"PHASE3","title":"Efficacy of Cannabinoids in Amyotrophic Lateral Sclerosis or Motor Neurone Disease","status":"UNKNOWN","sponsor":"Gold Coast Hospital and Health Service","startDate":"2019-01-09","conditions":"Amyotrophic Lateral Sclerosis, Motor Neuron Disease","enrollment":17},{"nctId":"NCT04997954","phase":"PHASE4","title":"EMERALD TRIAL Open Label Extension Study","status":"UNKNOWN","sponsor":"Gold Coast Hospital and Health Service","startDate":"2021-05-17","conditions":"Amyotrophic Lateral Sclerosis, Cannabis, CBD","enrollment":7},{"nctId":"NCT03549819","phase":"PHASE3","title":"Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2021-12-15","conditions":"Generalized Anxiety Disorder, Social Anxiety Disorder, Panic Disorder","enrollment":50},{"nctId":"NCT01964547","phase":"PHASE4","title":"A Randomized Study of Sativex on Cognitive Function and Mood: Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2012-01","conditions":"Multiple Sclerosis, Spasticity","enrollment":121},{"nctId":"NCT01610700","phase":"PHASE3","title":"An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2001-05","conditions":"Multiple Sclerosis","enrollment":160},{"nctId":"NCT01606189","phase":"PHASE3","title":"A Study to Compare Sublingual Cannabis Based Medicine Extracts With Placebo to Treat Brachial Plexus Injury Pain","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2001-12","conditions":"Pain","enrollment":48},{"nctId":"NCT01606202","phase":"PHASE3","title":"A Study of Cannabis Based Medicine Extracts and Placebo in Patients With Pain Due to Spinal Cord Injury","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2002-07","conditions":"Pain","enrollment":116},{"nctId":"NCT01610713","phase":"PHASE3","title":"An Study to Investigate the Efficacy of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2001-05","conditions":"Multiple Sclerosis","enrollment":154},{"nctId":"NCT01604265","phase":"PHASE3","title":"A Study of Sativex in the Treatment of Central Neuropathic Pain Due to Multiple Sclerosis","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2002-03","conditions":"Multiple Sclerosis, Neuropathic Pain","enrollment":66},{"nctId":"NCT01812616","phase":"PHASE1, PHASE2","title":"A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2014-09","conditions":"Cancer","enrollment":21},{"nctId":"NCT02073474","phase":"","title":"An Observational Post-Marketing Safety Registry of Sativex®","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2011-02","conditions":"Multiple Sclerosis, Diabetes, Cancer","enrollment":978},{"nctId":"NCT01898520","phase":"PHASE3","title":"A Safety, Efficacy and Tolerability Study of Sativex for the Treatment of Spasticity in Children Aged 8 to 18 Years","status":"COMPLETED","sponsor":"Jazz Pharmaceuticals","startDate":"2013-12","conditions":"Cerebral Palsy","enrollment":72},{"nctId":"NCT04261166","phase":"PHASE1","title":"A Phase I Open Label Study to Assess PK and Safety of Plant Cannabis Extract","status":"COMPLETED","sponsor":"Breath of Life International Pharma Ltd","startDate":"2019-07-24","conditions":"Healthy","enrollment":76},{"nctId":"NCT05626959","phase":"PHASE2, PHASE3","title":"Evaluating the Efficacy of NTI164 in Young People With Autism Spectrum Disorder","status":"UNKNOWN","sponsor":"Fenix Innovation Group","startDate":"2022-11-30","conditions":"Autism Spectrum Disorder","enrollment":54},{"nctId":"NCT05516407","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Oral Full-Spectrum Medicinal Cannabis Plant Extract in Children With Autism Spectrum Disorder.","status":"UNKNOWN","sponsor":"Fenix Innovation Group","startDate":"2021-04-01","conditions":"Autism Spectrum Disorder","enrollment":18},{"nctId":"NCT04763252","phase":"","title":"Canadian Registry for the Use of Spectrum Therapeutics Cannabis Products in Subjects With Chronic Pain","status":"UNKNOWN","sponsor":"Canopy Growth Corporation","startDate":"2021-01-25","conditions":"Chronic Pain","enrollment":500},{"nctId":"NCT04976738","phase":"PHASE1, PHASE2","title":"A Study of Cybis™ 10:25 THC:CBD Oil in Adults With Chronic Back/Neck Pain","status":"COMPLETED","sponsor":"Cymra Life Sciences","startDate":"2021-09-20","conditions":"Chronic Pain, Neck Pain, Back Pain","enrollment":28},{"nctId":"NCT05413187","phase":"PHASE2","title":"A Trial to Assess the Efficacy and Safety of Medical Grade Cannabis in Children Diagnosed With Autism Spectrum Disorder","status":"WITHDRAWN","sponsor":"TO Pharmaceuticals","startDate":"2020-09-01","conditions":"Autistic Disorder","enrollment":""},{"nctId":"NCT04592159","phase":"PHASE2, PHASE3","title":"Study of the Safety and Efficacy of Nabiximols Oromucosal Spray Versus Placebo in Patients With Post-traumatic Stress Disorder","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2021-02-01","conditions":"Post-Traumatic Stress Disorder","enrollment":""},{"nctId":"NCT04808531","phase":"PHASE3","title":"NanaBis™ an Oro-buccal Administered delta9-Tetrahydrocannabinol (d9-THC) & Cannabidiol (CBD) Medicine for the Management of Bone Pain From Metastatic Cancers","status":"UNKNOWN","sponsor":"Medlab Clinical","startDate":"2023-11","conditions":"Cancer Related Pain","enrollment":360},{"nctId":"NCT03639064","phase":"PHASE2","title":"Cannabis Oil for Pain in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2020-12-01","conditions":"Parkinson Disease","enrollment":15},{"nctId":"NCT03328676","phase":"PHASE2","title":"The Effect of Cannabis on Dementia Related Agitation and Aggression","status":"COMPLETED","sponsor":"TO Pharmaceuticals","startDate":"2017-12-07","conditions":"Agitation Related to Dementia","enrollment":64},{"nctId":"NCT04764552","phase":"NA","title":"Yeahhh Baby! Ointment on Hip and/or Knee Pain in Men and Women","status":"COMPLETED","sponsor":"University of Memphis","startDate":"2021-02-09","conditions":"Joint Pain","enrollment":20},{"nctId":"NCT02983695","phase":"PHASE1","title":"Cannabinoid Therapy for Pediatric Epilepsy","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2017-02-02","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT05115318","phase":"","title":"The Effect of Medical Cannabis on Tics, Premonitory Urge and Psychiatric Comorbidity in Adults With Tourette Syndrome","status":"COMPLETED","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2020-07-01","conditions":"Tourette Syndrome, Cannabis","enrollment":18},{"nctId":"NCT05106504","phase":"","title":"Effect of Medical Cannabis for Non-motor Symptoms of Parkinson's Disease","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2021-09-02","conditions":"Bladder, Overactive, Parkinson Disease","enrollment":100},{"nctId":"NCT03929835","phase":"PHASE2","title":"Study to Investigate the Efficacy and Safety of Cannabis Oil for the Treatment of Subjects With Hidradenitis Suppurativa","status":"WITHDRAWN","sponsor":"TO Pharmaceuticals","startDate":"2020-09-01","conditions":"Hidradenitis Suppurativa","enrollment":""},{"nctId":"NCT03664141","phase":"PHASE3","title":"Impact of Cannabis Oil on Nutrition in Hemodialysis Patients Study (ICON-HP Study)","status":"WITHDRAWN","sponsor":"Assaf-Harofeh Medical Center","startDate":"2018-09-15","conditions":"Protein-Energy Malnutrition, Hemodialysis, Appetite Disorders","enrollment":""},{"nctId":"NCT03717272","phase":"PHASE2","title":"Effect of AEF0117 on Subjective Effects of Cannabis in CUD Subjects","status":"COMPLETED","sponsor":"Aelis Farma","startDate":"2018-10-23","conditions":"Marijuana Abuse","enrollment":29}],"_emaApprovals":[],"_faersSignals":[{"count":10,"reaction":"FATIGUE"},{"count":9,"reaction":"DIZZINESS"},{"count":9,"reaction":"HEADACHE"},{"count":9,"reaction":"NAUSEA"},{"count":8,"reaction":"PAIN"},{"count":8,"reaction":"PYREXIA"},{"count":7,"reaction":"OFF LABEL USE"},{"count":7,"reaction":"VOMITING"},{"count":6,"reaction":"ASTHENIA"},{"count":6,"reaction":"TREMOR"}],"_approvalHistory":[],"publicationCount":186,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["MPL-005","Extrato de Cannabis sativa GreenCare 79.14 mg/mL","Avidekel Oil"],"phase":"marketed","status":"active","brandName":"Cannabis oil","genericName":"Cannabis oil","companyName":"Assaf-Harofeh Medical Center","companyId":"assaf-harofeh-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cannabis oil contains cannabinoids (primarily THC and CBD) that interact with endocannabinoid receptors (CB1 and CB2) throughout the central and peripheral nervous systems to modulate pain, inflammation, and other physiological processes. Used for Chronic pain, Chemotherapy-induced nausea and vomiting, Multiple sclerosis-related spasticity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}